Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Genovese

Showing results (31-40 of 172) with videos related to

Pageof 18
Sort By:
The Journal of Rheumatology|July 17, 2012
Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapyMark C Genovese, Michael Schiff, Michael Luggen, et al.
The Journal of Rheumatology|April 17, 2009
Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritisPaul Emery, Mark C Genovese, Ronald van Vollenhoven, et al.
Arthritis and Rheumatism|April 16, 2002
Long-term followup of patients treated with total lymphoid irradiation for lupus nephritisMark C Genovese, Zuzana Uhrin, Daniel A Bloch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 11, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or ObesityJoseph F Merola, Cynthia E Kartman, Peter Fischer, et al.
The New England Journal of Medicine|October 1, 2010
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritisMichael E Weinblatt, Arthur Kavanaugh, Mark C Genovese, et al.
The Journal of Rheumatology|May 23, 2007
A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the handsMolly D Magnano, Eliza F Chakravarty, Corrie Broudy, et al.
Arthritis Research & Therapy|January 23, 2020
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritisBernard Combe, Proton Rahman, Hideto Kameda, et al.
BMC Musculoskeletal Disorders|May 28, 2016
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abataceptRieke Alten, Clifton O Bingham, Stanley B Cohen, et al.
The Journal of Rheumatology|January 17, 2016
Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic ArthritisPhilip J Mease, Mark C Genovese, Alex Mutebi, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid ArthritisMark C Genovese, Daniel K Braun, Janelle S Erickson, et al.
Pageof 18

Showing results (31-40 of 172) with videos related to

Sort By:
Pageof 18
The Journal of Rheumatology|July 17, 2012
Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapyMark C Genovese, Michael Schiff, Michael Luggen, et al.
The Journal of Rheumatology|April 17, 2009
Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritisPaul Emery, Mark C Genovese, Ronald van Vollenhoven, et al.
Arthritis and Rheumatism|April 16, 2002
Long-term followup of patients treated with total lymphoid irradiation for lupus nephritisMark C Genovese, Zuzana Uhrin, Daniel A Bloch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 11, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or ObesityJoseph F Merola, Cynthia E Kartman, Peter Fischer, et al.
The New England Journal of Medicine|October 1, 2010
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritisMichael E Weinblatt, Arthur Kavanaugh, Mark C Genovese, et al.
The Journal of Rheumatology|May 23, 2007
A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the handsMolly D Magnano, Eliza F Chakravarty, Corrie Broudy, et al.
Arthritis Research & Therapy|January 23, 2020
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritisBernard Combe, Proton Rahman, Hideto Kameda, et al.
BMC Musculoskeletal Disorders|May 28, 2016
Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abataceptRieke Alten, Clifton O Bingham, Stanley B Cohen, et al.
The Journal of Rheumatology|January 17, 2016
Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic ArthritisPhilip J Mease, Mark C Genovese, Alex Mutebi, et al.
The Journal of Rheumatology|December 17, 2015
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid ArthritisMark C Genovese, Daniel K Braun, Janelle S Erickson, et al.
Pageof 18